A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results.
Karen Kelly
No relevant relationships to disclose
Nasser K. Altorki
No relevant relationships to disclose
Wilfried Ernst Erich Eberhardt
Consultant or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck; Merck Serono; Novartis; Pfizer; Roche; Teva
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Merck Serono; Novartis; Pfizer; Roche
Research Funding - Lilly
Mary E.R. O'Brien
No relevant relationships to disclose
David R. Spigel
No relevant relationships to disclose
Lucio Crino
No relevant relationships to disclose
Chun-Ming Tsai
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Pfizer; Roche
Joo-Hang Kim
Research Funding - Lilly; Pfizer; Roche
Eun Kyung Cho
No relevant relationships to disclose
Aleksandra Szczesna
No relevant relationships to disclose
Otto Burghuber
No relevant relationships to disclose
Philip C. Hoffman
No relevant relationships to disclose
Shaf Keshavjee
No relevant relationships to disclose
Sergey Orlov
No relevant relationships to disclose
Piotr Serwatowski
No relevant relationships to disclose
Jiuzhou Wang
Employment or Leadership Position - Astellas Pharma
Margaret A. Foley
Employment or Leadership Position - Astellas Pharma
Julie D. Horan
Employment or Leadership Position - Novella Clinical
Jung Wook Park
Employment or Leadership Position - Astellas Pharma
Frances A. Shepherd
Consultant or Advisory Role - Astellas Pharma; OSI Pharmaceuticals; Roche
Honoraria - Roche